AbbVie Inc. (ABBV)
AbbVie Inc. (ABBV) Stock Price, Analysis & Data
| Bid | 250.12 |
| Market Cap | 442.22B |
| Revenue (ttm) | 64.39B |
| Net Income (ttm) | 6.27B |
| Beta | 0.28 |
| EPS (ttm) | 3.53 |
| PE Ratio (ttm) | 70.89 |
| Forward PE | 15.37 |
| P/B (ttm) | -74.50 |
| P/S (ttm) | 6.87 |
| Earnings Date | Oct 29, 2026 |
| Ask | 250.22 |
| Volume | 2,321,199 |
| Avg. Volume (20D) | 6,735,285 |
| Open | 252.94 |
| Previous Close | 248.76 |
| Day's Range | 249.73 - 255.29 |
| 52-Week Range | 190.75 - 267.47 |
| Analyst | Buy |
| Price Target | 280 (11.89%) |
| Dividends | $6.92 (2.77%) |
| Ex-Dividend Date | Jul 15, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis f...
Financial Performance
In 2025, AbbVie's revenue was 61.16B, an increase of 8.57% compared to the previous year's 56.33B. Earnings were 4.23B, a decrease of -1.22%.
Financial StatementsAnalyst Forecast
According to 28 analyst ratings, the average rating for ABBV stock is "Buy". The 12-month stock price forecast is 280, which is upside of 11.89% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
